Abstract
We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003
| Original language | English (US) |
|---|---|
| Pages (from-to) | 285 |
| Number of pages | 1 |
| Journal | Molecular Genetics and Metabolism |
| Volume | 131 |
| Issue number | 1-2 |
| DOIs |
|
| State | Published - Sep 1 2020 |
Bibliographical note
Publisher Copyright:© 2020 The Author(s)
Fingerprint
Dive into the research topics of 'Corrigendum to "The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII" [Mol Genet Metab 2020 Mar;129(3):219-227]'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS